Pamrevlumab + nab-paclitaxel/gemcitabine as 1L &amp; 2L therapy in mPDAC #ASCOGI25
🔎Precision Promise (PrP) Bayesian platform trial
👉Pam + GA did not improve OS vs GA in 1L/2L mPDAC
🧐Interesting trail design to enhance drug testing
🧐Same story for #PDAC ...
@myESMO
#ASCOGI25 #PDAC